Survivorship, version 2.2017: Clinical Practice Guidelines in Oncology Journal Article


Authors: Denlinger, C. S.; Sanft, T.; Baker, K. S.; Baxi, S.; Broderick, G.; Demark-Wahnefried, W.; Friedman, D. L.; Goldman, M.; Hudson, M.; Khakpour, N.; King, A.; Koura, D.; Kvale, E.; Lally, R. M.; Langbaum, T. S.; Melisko, M.; Montoya, J. G.; Mooney, K.; Moslehi, J. J.; O'Connor, T.; Overholser, L.; Paskett, E. D.; Peppercorn, J.; Rodriguez, M. A.; Ruddy, K. J.; Silverman, P.; Smith, S.; Syrjala, K. L.; Tevaarwerk, A.; Urba, S. G.; Wakabayashi, M. T.; Zee, P.; Freedman-Cass, D. A.; McMillian, N. R.
Article Title: Survivorship, version 2.2017: Clinical Practice Guidelines in Oncology
Abstract: Many cancer survivors experience menopausal symptoms, including female survivors taking aromatase inhibitors or with a history of oophorectomy or chemotherapy, and male survivors who received or are receiving androgen-ablative therapies. Sexual dysfunction is also common in cancer survivors. Sexual dysfunction and menopause-related symptoms can increase distress and have a significant negative impact on quality of life. This portion of the NCCN Guidelines for Survivorship provide recommendations for screening, evaluation, and treatment of sexual dysfunction and menopausal symptoms to help healthcare professionals who work with survivors of adult-onset cancer in the posttreatment period. © 2017 JNCCN-Journal of the National Comprehensive Cancer Network.
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 15
Issue: 9
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2017-09-01
Start Page: 1140
End Page: 1163
Language: English
DOI: 10.6004/jnccn.2017.0146
PROVIDER: scopus
PUBMED: 28874599
PMCID: PMC5865602
DOI/URL:
Notes: Review -- Export Date: 2 October 2017 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Shrujal S Baxi
    107 Baxi